Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Abstract: The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2a receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about ?40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Abstract: The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm.

Abstract: The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm.

Abstract: The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm.

Abstract: This invention provides a topical drug formulation and methods for the preparation thereof. This invention further provides the use of said drug formulation in pharmaceutical compositions and methods of treating mammals. This invention also provides the use of said drug formulation in pharmaceutical compositions for dermatological and transdermal applications. More specifically, this invention provides an aqueous-based drug formulation which has increased storage stability and controlled drug release upon application. The present application also describes materials and methods useful in creating such drug formulations.

Abstract: The invention described herein provides a solid dispersion of Indirubin, a pharmaceutical composition comprising the solid dispersion of Indirubin, a process for preparing the solid dispersion and pharmaceutical composition, and a method of using the pharmaceutical composition.

Abstract: The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm.